登录 | 注册    关注公众号  
微信公众号
搜索

LOXL2信息

英文名称:Lysyl oxidase homolog 2
中文名称:赖氨酰氧化酶同源蛋白-2
靶点别称:EC:1.4.3.13,EC 1.4.3,Lysyl oxidase-like protein 2,Lysyl oxidase homolog 2,LOXL2,Lysyl Oxidase Like 2,Lysyl Oxidase-Related Protein WS9-14,Lysyl Oxidase-Related Protein 2,Lysyl Oxidase-Like 2 Delta E13,Lysyl Oxidase-Like 2 Protein,Lysyl Oxidase Related 2,Lysyl Oxidase-Like 2,EC 1.4.3.13,WS9-14,LOR2,LOR
上市药物数量:0
临床药物数量:4
最高研发阶段:临床一期

LOXL2产品列表

 
评论(0)
 

LOXL2 分子别名

Lysyl oxidase homolog 2,LOXL2

LOXL2 分子背景

Lysyl oxidase homolog 2 is also known as LOXL2, Lysyl oxidase-like protein 2, which is expressed in many tissues, highest expression in reproductive tissues, placenta, uterus and prostate, Up-regulated in a number of cancers cells and tissues. LOXL2 mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). When secreted in extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. LOXL2 acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. When nuclear, acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. LOXL2 acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation.

LOXL2 前沿进展

LOXL2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
PXS-5338 PXS-5338 临床一期 Pharmaxis 非酒精性脂肪肝, 肝硬化, 肾脏纤维化, 肺纤维化 详情
PXS-5382 PXS-5382; PXS-5382A 临床一期 Pharmaxis 非酒精性脂肪肝, 特发性肺纤维化, 肾脏纤维化 详情

消息提示

请输入您的联系方式,再点击提交!

确定